Figure 3. Targeted AM depletion ameliorates genotype-specific metastatic phenotype in a primary tumor-independent manner.

(A) Treatment schedule for Lyz2-Cre^+/+ YFP^+/– Ctnnb1^Ex3Δ/wt and Lyz2-Cre^+/+ YFP^+/– mice treated with clodronate liposomes or vehicle control until endpoint 14 days after tail vein injection of E0771.ML-1 cells. (B) Relative abundance of lung CD45⁺Ly6G^–CD24^–CD64⁺CD11b^loCD11c⁺ AMs at endpoint as described in A. (C) Bioluminescence images, representative of 3 independent experiments, and (D) quantification of mice represented in C at endpoint. (B and D) The mean ± SEM values are shown and represent 5–9 individual mice. Statistical analysis is based on 1-way ANOVA with the Holm-Šídák correction applied for multiple comparisons (B and D); * = P < 0.05.